Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Imaging SV2A in Mood Disorders


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02734602

Organisation Name: Yale University

Overal Status: Recruiting

Start Date: April 2016

Last Update: February 10, 2020

Lead Sponsor: Yale University

Brief Summary: This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD.

After a screening process to determine eligibility, all subjects will participate in an MRI, and 2-3 PET scans with the administration of ketamine for one of the scans. Cognitive testing and a stress test may also be done on scan days.

Conditions:
  • Major Depressive Disorder
  • Post-Traumatic Stress Disorder


Total execution time in seconds: 0.15174293518066